Can a Two-Drug combo outsmart tough lung cancer?
NCT ID NCT07742956
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This phase II trial is testing whether combining an experimental drug called ALK201 with an existing immunotherapy, ivonescimab, can help people with advanced squamous non-small cell lung cancer. The study includes adults whose tumors have a specific marker (FGFR2b) and who have not responded to standard treatments. Researchers will evaluate the safety, side effects, and anti-tumor activity of the combination, starting with dose escalation and then moving to dose optimization in two groups based on PD-L1 expression levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ALK201 for injection combined with ivonescimab injection
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced squamous non-small cell lung cancer, potentially improving tumor shrinkage and delaying disease progression.
- What could go wrong
- This is an early-phase trial, so the combination may not work as hoped or could cause significant side effects. The results will need confirmation in larger studies before any new treatment becomes available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Drug duo aims to tackle tough lung cancers after first treatment fails
- Blood test may let cancer patients take safe breaks from immunotherapy
- New combo aims to stall lung cancer when targeted pills start to fail
- New hope for lung cancer patients: drug combo targets tough tumors